The Liver Meeting 2023-2023 TLM Debrief Session (Cholestasis Debrief)

Video Transcription

Video Summary

Dr. Gideon Hirshfield from the Toronto Centre of Liver Disease provided a debrief on cholestatic liver disease, emphasizing the importance of ASLD 2023 in advancing treatments for rare liver diseases. He highlighted the need for prompt diagnosis, individualized therapy, and prevention of end-stage liver disease. The debrief covered various studies presented at the conference, including the use of human tissue for disease modeling, biomarker identification, and therapeutic targets. Notable late-breaking studies focused on integrin inhibition in PSC and the efficacy of different treatments in PBC. The challenges of conducting clinical trials in rare diseases were discussed, along with the importance of patient symptoms and quality of life. The session underscored the ongoing efforts to improve care and outcomes for patients with cholestatic liver diseases.

Asset Caption

Gideon Hirschfield, FRCP PhD: Cholestasis Debrief

Keywords

Dr. Gideon Hirshfield

Toronto Centre of Liver Disease

cholestatic liver disease

ASLD 2023

rare liver diseases

clinical trials